Archive for the ‘oncology retractions’ Category
These two new retractions, in Genes and Development, stem directly from another paper by Weinberg and colleagues in Cell that will apparently be retracted, as the “same analytical methodology was used,” according to the notices [see bottom of the post for an update].
Weinberg is highly regarded, and at least 20 of his papers have been cited over a thousand times.
First author Scott Valastyan was a promising postdoc at the time of the paper’s publication. He was a 2011 Runyon Fellow at Harvard, a three-year, $156,000 award for outstanding cancer postdocs. He doesn’t seem to have published anything since 2012, though he is listed as a joint inventor with Weinberg on patents filed in 2009 and 2014.
Here are the notices for “Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis” (cited 73 times, according to Thomson Scientific’s Web of Knowledge) and “Activation of miR-31 function in already-established metastases elicits metastatic regression” (cited 54 times), both paywalled: Read the rest of this entry »
A former researcher at the University of Pittsburgh inflated the number of mice used in his experiments, and faked data in a number of images in a paper reporting the results, according to the Office of Research Integrity (ORI).
Dong Xiao admitting to having
intentionally fabricated data contained in a paper entitled ‘Guggulsterone inhibits prostate cancer growth via inactivation of Akt regulated by ATP citrate signaling,’ specifically Figure 6G,
A retracted 2008 paper originally flagged by Clare Francis has been republished in Environmental Health Perspectives with updated figures and new data.
According to the editor’s note appended to the newly published paper, there was no evidence of intentional misconduct on the part of the authors. The new paper went through peer review as an entirely new submission, and comes to the same conclusion as the original: Read the rest of this entry »
Hindawi journal PPAR Research has pulled a cancer immunology paper after discovering it contained almost no new information.
Instead, it was a Frankenstein-style stitch job, containing sentences ripped from 33 different papers. 18 of those ended up in the citations; for 15 more, the authors didn’t even do them that courtesy. You can see a meticulously color-coded call out here.
Researchers at the University of Pittsburgh have retracted a paper on using thalidomide, which led to an estimated 10,000 birth defects by the time the drug was pulled from the market in 1961, to prevent chemo-induced sterility.
Alkylating agents, which prevent DNA replication in cells, are a commonly-used cancer treatment. Unfortunately they also damage the ovaries and testes, sometimes causing infertility. The University of Pittsburgh scientists published a paper in Elsevier journal Fertility and Sterility in 2011 that suggested thalidomide, which causes severe birth defects when used during pregnancy, might help protect ovaries during chemo.
However, according to the notice, the authors tried and failed to replicate their results. They had two separate scientists who were not authors take a look at the results; everyone agreed that the original study incorrectly reported the number of primordial follicles, the precursor to mature eggs.
Take a look at figure one to the right and see if you can spot all the doubles.
Click here for a more zoomable image.
Here’s the notice for “Effect of ST3GAL 4 and FUT 7 on sialyl Lewis X synthesis and multidrug resistance in human acute myeloid leukemia,” a paper initially published in June: Read the rest of this entry »
A paper by a former postdoc at MD Anderson Cancer Center who “admitted to knowingly and intentionally falsifying” a figure has been retracted.
In August, the Office of Research Integrity announced that it had sanctioned Jun Fu for faking data in a study of the results of a mouse study of NVP-HSP990, a Novartis compound designed to fight brain tumors. Here’s the notice for the study in question, published in Cancer Research:
Read the rest of this entry »
A group of researchers at the Guangdong Academy of Medical Sciences in Guangzhou, China have retracted a paper that came out of a clinical trial on transarterial chemoembolization, a targeted kind of chemotherapy.
According to the notice, one of the authors mixed up the control samples with the clinical samples, and “could not recall which samples were in the wrong group.” The paper hasn’t yet been cited, according to Thomson Scientific’s Web of Knowledge.
Here’s the notice in Medical Oncology:
In June, a paper in Tumor Biology was retracted for at least four reasons, including bad data and hiding a trial sponsor (Merck). Some people who contributed work weren’t cited; at least one author had no idea his name would be on it. And that’s just what they tell us in the notice.
Here’s the notice for “Neutropenia and invasive fungal infection in patients with hematological malignancies treated with chemotherapy: a multicenter, prospective, non-interventional study in China:” Read the rest of this entry »